# A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Source: https://onco.cc/trials/nct04554914/  
OnCo record `nct04554914` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tabelecleucel in brain and spinal cord tumours, sarcomas and uterine sarcoma, run by Pierre Fabre Medicament, active and no longer recruiting.

## Summary

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases is a phase 2 interventional study registered as NCT04554914 by Pierre Fabre Medicament, with 190 participants enrolled, started 2021-07-14 and due to reach its primary completion in 2027-06. Interventions recorded: Tabelecleucel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04554914
- Phase: 2
- Setting: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein Barr Virus Associated Diseases (EBVision)
- Sponsor: Pierre Fabre Medicament
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT04554914: https://clinicaltrials.gov/study/NCT04554914

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Uterine sarcoma](https://onco.cc/cancers/uterine-sarcoma/)
- drugs: [Tabelecleucel](https://onco.cc/drugs/tabelecleucel/)

---
JSON: https://onco.cc/api/v1/entities/nct04554914.json